



What's New in CAS STNext?

March 2025

© 2025 American Chemical Society. All rights reserved.

40 Years of STN®

Connecting the past, present, and the future of IP Search

- STN, the Scientific & Technical Information Network, was born from an idea that was ambitious for its time.
- A global network that would provide seamless access to a fragmented collection of leading scientific databases stored on different continents.
- STN was launched in May 1984



1984



1982




1984



1989

The Evolution of STNnext

Number of databases in STN




STN was launched as a collaborative project by CAS and FIZ Karlsruhe with 4 databases.

1987 The Japan Science and Technology Agency was involved in covering the Asian market.

In 1993 Derwent Information agreed to load its Derwent World Patents Index (DWPI) file on STN.

The Evolution of STNNext

CAS today in figures



Hundred of Millions
of chemical substances



48 of the top 50
pharma companies rely
on CAS



10 of the top 10
Global patent offices
rely on CAS



100 of the top 100
Universities rely on CAS



**95 % of the world's
patent applications**
are reviewed by patent
offices that use STN



Agenda

- STN Interface enhancements
- Database enhancements and reloads
 - Enhancements to full-text patent files
- Ultimate Owner/acquisition of patent rights
- Unitary Patent Information

Updated Structure Editor

New **Structure Editor Toolbar** options:

- **Floating**: toolbars are detached and movable
- **Attached**: toolbars are integrated into the Structure Editor canvas
- Placement and visual contrast of pop-up menus has been improved
- Higher-contrast fonts to improve overall readability




File Import Window Redesign

For Structures, Sequences and Scripts

Provides more visibility and flexibility for importing files:

- Importing up to **10 files** simultaneously
- **Interactive list** of selected files:
 - Edit file names
 - Add/remove files to be imported
- Overwrite file functionality:
 - “File name already exists in this location” messaging appears when a duplicate name occurs
 - If left blank, the system assigns an auto-generated name





Creating Reports


Access via the **Create Report** option

The new report wizard guides users through the steps of:

- Select answers
- Choose a template (ability to create a custom template)
- Select hit highlighting options
- Apply additional formatting and download



To create a customized template, select "copy template"



Fields can be added or removed, and their order changed. The template can be saved for future use.

National Register Links in Transcripts and Reports

Select options in CAS STNext settings

National office (Register) and Interactive Claims Viewer hyperlinks can be included in transcript and report exports:

Settings

Transcript Download

Prompt at Logoff/Logoff Hold ☐ ON

Transcript Format RTF ▾

Document Hit Highlight Color Blue ▾

Include Link Information Table ☐ ON

PATENT FAMILY INFORMATION				
+----- Publications -----+ +----- Applications -----+ +- STI --+				
CN 115357816	A	20221118	CN 2022-10533886	A 20220517 A
EP 4092997	A1	20221123	EP 2022-173718	A 20220517 A
+----- Priorities -----+				
US 2021-63189666	P	20210517		
US 2021-63197224	P	20210604		
US 2022-17744599	A	20220513		
LINK INFORMATION				
PUBLICATIONS		APPLICATIONS	REGISTER	CLAIMS VIEWER
CN 115357816 A		CN 2022-10533886	Register	
EP 4092997 A1		EP 2022-173718	Register Federated Reg. Claims	

Agenda

- STN Interface enhancements
- Database enhancements and reloads
 - Enhancements to full-text patent files
- Ultimate Owner/acquisition of patent rights
- Unitary Patent Information

Updates on Thesauri in CAS STNNext

Incorporation and Adjustment of terms and codes

- 1) Updated MeSH (Medical Subject Headings) in **MEDLINE** and Emtree in **EMBASE** for terminology in the area of biomedicine, pharmacology and medical devices
 - New headings added in MESH e.g. on Post-Acute COVID-19 Syndrome
 - New drug, non-drug terms and medical device trade names were added in Emtree e.g. on *head and neck tumors*, and *metabolic disorders*, and taxonomies and terminology for various diseases were updated
- 2) Revised Manual Codes in **DWPI**
 - New Manual Codes e.g. for *monomers containing sulfur or silicon*, *specific modification on messenger RNA*, and *telecommunications network proxy and addressing*
 - More information on added or changed terms/codes in **CAS STNNext Help** and links

If you run Alerts (SDIs) in the respective databases, we recommend reviewing the used terminology/codes!

Extended Patent Office Coverage in CAplus

- CAplus went from 64 to **109 patent offices**
- Additional bibliographic data for:

AM, BA, BO, BY, CL, CU, CY, DO, EC, ID, GE, GT, HN, IR, IS, JO, KE, KG, KZ, MA, ME, MN, MT, MW, NI, PA, PE, PK, PY, RS, SA, SM, SV, TH, TJ, TN, TT, UA, UY, UZ, VE, VN, YU, ZM, ZW

>16K new basic patents


>91K patent family members

These additions enhance the patent family data. **Deep indexing will not** be performed for these additional authorities.

Extended Patent Office Coverage in CPlus

plus WO, GCC,
ARIPO and
Eurasia regions

-  **Green:** fully indexed
-  **Yellow:** bibliographic data
-  **Light blue:** no data




Powered by Bing
© Australian Bureau of Statistics, GeoNames, Microsoft, Navinfo, Open Places, OpenStreetMap, Overture Maps Foundation, TomTom, Zenrin

CAS PatentPak Available in Marpat

Access the original patent

- Now available in CAplus, USPATFULL/USPAT2 and **MARPAT**
- Instant connection to searchable, full-text patents from major patent offices
- CAS scientists review each patent and identify new substances for CAS REGISTRY inclusion
- They mark the specific location of substances in the text during analysis
- Algorithmic processing with human intervention allows previously registered substances to be located and annotated in backfile documents



"I analyzed this entire patent and located the important chemistry so you don't have to."

*Mona Aasmul
Senior Scientific
Information Analyst*

Claim Tagging in PatentPak

- Substances and sequences from Claims systematically tagged, for US, WO, CN, KR and JP patents
- Time coverage: US (1975-), WO (2010-), CN (2011-), KR (2011-) and JP (2010-)

Display:

- A** Substances with claim tag appear first in PPAK and display
- B** **Jump to Claims** function available in PPAK Viewer; Claim tag added to page link

A PPAK

1421373-65-0, Pg 37 Claim

1430101-92-0, Pg 37 Claim

1442472-39-0, Pg 37 Claim

ALL, STD and HITPPAK formats will show claim tag in **PPAK** display

B



PatentPak

PAGE



37

/71


CLAIMS

Jump To Claims

Viewer has **Jump to claims** option in the top bar

Claim tag linked to substance entries in the left panel of the viewer

CAS RN 1430101-92-0



Analyst Markup Locations (1)


[page 37 - Claim](#)

14. The combination drug for use according to any one of claims is selected from the group consisting of: SCO-101, SCO-201, Estrone, Saquinavir, Omeprazole, Hesperetin, Genistein, Nel

Substance Claimed Role

Derived from claimed tagged compounds

PPAK



RL: PAC (Pharmacological activity); **SCLM (Substance claimed)**;

- New role for substances described in claims: **SCLM**
- Substance class may be claimed but specific substances may not be specifically listed in the claims
- In the early years of PatentPak, the CAS Indexer focused more on exemplified substances
- Available to every STNext user (no PatentPak add-on required)

Example of Claimed Drug


Gabapentin was searched by structure to include derivatives

FILE 'REGISTRY' ENTERED AT 09:22:18 ON 15 OCT 2024

L1 1 S GABAPENTIN/CN
L2 STRUCTURE UPLOADED
L3 5842 S L2 SSS FUL

FILE 'CAPLUS' ENTERED AT 09:24:31 ON 15 OCT 2024

L4 7911 S L3
L5 2207 S L4 AND P/DT
L6 1774 S L5 AND PPAK/FA
L7 1042 S L3/SCLM
L8 1614 S L6 AND (WO OR US OR CN OR JP OR KR)/PC.B
L9 1244 S L8 AND GABAPENTIN?/CLM
L10 289 S L9 NOT L7
L11 87 S L7 NOT L9
L12 1331 S L7 OR L9



Example of Display

Display ALL

TI Method for the prediction of progression or prognosis of the response of a
subject suffering from acute organ damage
UO PLUS VITECH S L
PI WO 2022038131 A1 20220224
IT 60142-96-3, Gabapentin 478296-72-9, Gabapentin
enacarbil
RL: PAC (Pharmacological activity); SCLM (Substance claimed);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for the prediction of progression or prognosis of the response
of a subject suffering from acute organ damage)

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

PPAK

51312-12-0, Hemokinin, [Pg 51 Claim](#)

50-00-0, Formaldehyde, [Pg 40](#)

64-17-5, Ethanol, [Pg 29](#)

60142-96-3, Gabapentin, [Pg 53 Claim](#)

147116-64-1, Ezlopitant, [Pg 53 Claim](#)

147116-67-4, Maropitant, [Pg 53 Claim](#)

148553-50-8, Pregabalin, [Pg 53 Claim](#)

168266-90-8, Vofopitant, [Pg 53 Claim](#)

478296-72-9, Gabapentin enacarbil, [Pg 53 Claim](#)

ALL format will show both
the **SCLM role** and the
claim tag in **PPAK**

Enhanced Performance of Derwent World Patents Index

30+ Years of DWPI on STN



- Increased coverage
- More database updates
- More patent authorities
- More timely
- **Higher performance**

from 6.3 M records to >67 M records
from 52 to 104 updates per year
from 31 to 60 patent authorities
for basic patents and equivalents
for searching and analyzing

Properties and Reactions Now Available in REAXYFILESUB

ReaxysFileSub has been reloaded with reactions and properties

- Now available from 1771-**present**, updates 2x/week
- Reaxys legacy file is no longer continued

5 Property sections cover 110 properties:

- physical prop., spectroscopy, state of aggregation, multicomponent systems, further prop.
- New search ¹ and display fields

¹	/FA.P	Availability for properties
	/KW	Keywords
More info in Database summary sheet and User Guide		

Reaction data is available on two different detail levels:

- Reaction identification data (reactions with same reactants and products are combined to same reaction ID)
- Reaction details: explicit information about reaction conditions


➔ Consult User Guide Properties and Reactions

Properties and Reactions Now Available in REAXYSFILESUB

- Display of specific properties of the substance Methoprene:

1

L5 ANSWER 6 OF 6 REAXYSFILESUB COPYRIGHT 2024 ELSEVIER INC. on STN.
AN 1913191 REAXYSFILESUB
RN 40596-69-8
CN methoprene; Methopren
SD acyclic
MF C19 H34 O3
CMF C19 H34 O3
LSF C19H34O3
INCHI NFGXHKASABOEWE-LDRANXPESA-N
AINCHI NFGXHKASABOEWE-LDRANXPEN
MW 310.477
MARKREF.CNT 1
REC 4799
ED Entered STN: 14 Jul 2020
Last updated on STN: 21 Aug 2024



The chemical structure of Methoprene is shown as a skeletal formula. It features a branched alkyl chain with a terminal methoxy group, a trans-double bond, a ketone group, and another trans-double bond, ending in a branched alkyl group.

2

IR spectroscopy (3)

Keyword (.KW)	Solvent (.SOL)	Comment (.CMT)	Ref(s) (REF)
FT-IR	neat (no solvent)	1710 - 970 cm ⁻¹ (-1)	1
FT-IR			1
Spectrum			2

1. AN 431732: Patent, WO 2007041127 A1
2. AN 5556924: Journal: Novak, Lajos et al., Liebigs Ann. Chem. (1982), No.6, pp. 1173 - 1182

UV/VIS spectroscopy (1)

Keyword (.KW)	Absorption Max. (.AM) (nm)	Ext./Abs. Coeff. (.EAC) (l*mol ⁻¹ *cm ⁻¹)	Ref(s) (REF)
Absorption maxima	262	16600	1

1. AN 5500966: Journal: Odinkov, V. N. et al., J. Org. Chem. USSR (Engl. Transl.) (1989) Vol. 25, No.4.1, pp. 650 - 653

=> **HELP PROPERTIES** or consult database summary sheet

Properties and Reactions Now Available in REAXYSFILESUB

- The availability of 110 properties is searchable with the new field availability search field **/FA.P**

L1 STRUCTURE UPLOADED

=> s 11 exa full

L2 54 SEA EXA FUL L1

=> s 12 and mp/fa.p

L3 9 L2 AND MP/FA.P

=> D


AN 4194670 REAXYSFILESU

RN 63968-64-9

CN Artemisinin; artemisinine; ART

SD heterocyclic

MF C15 H22 O5



Melting Point (35)

Value	Solvent	Location	
Ref(s)			
(MP)	(.SOL)	(.LO)	
(REF)			
(Cel)			
=====+=====+=====+=====			
=====			
153 - 154	cyclohexane	Page/Page column 74	1
153 - 154	cyclohexane	Page/Page column 74	1
153 - 154	cyclohexane	Paragraph 0081	2
153 - 154	cyclohexane	Paragraph 0081	2
153 - 154	cyclohexane	Page/Page column 57	3
MF	C15 H22 O5		
...			

Sequence Enhancements - Combined Alignment

- New display format available in GENESEQ, USGENE & PATGENE
- Combining results from BLAST search and separate GETSEQ search
- D ALIGNC
 - Shows both alignments in one sequence match

Display – D BIB SCORE ALIGNNC

```

L6      ANSWER 1 OF 914 GENESEQ COPYRIGHT 2025 CLARIVATE ON STN.
AN      AYN11564      GENESEQ ED 20211030 UP 20220114
      DED 20110217 DUPD 20220113 Full-text
TI      Producing members of specific binding pairs - by expression in
      recombinant host cells with a secreting replicable genetic display
      package.
IN      Bonnert TP; Chiswell DJ; Clackson TP; Griffiths AD; Holliger KP;
      Hoogenboom HRJ; Jackson RH; Johnson KS; Marks JD; Mccafferty J; Pope AR;
      Winter GP
PA      MEDICAL RES COUNCIL (MRCX)
      MEDIMMUNE LTD (ASTR)
LA      English
DT      Patent
PI      US 20100317540      A1      20101216
PIT      USA1 FIRST PUBLISHED PATENT APPLICATION [FROM 2001 ONWARDS]
AI      US 2010-772829      20100503
PRAI    GB 1990-15198      19900710
      GB 1990-22845      19901019
      GB 1990-24503      19901112
      GB 1991-4744      19910306
      GB 1991-10549      19910515
      WO 1991-GB1134      19910710
      US 1993-971857      19930108
      US 1995-484893      19950607
      US 1999-417479      19991013
      US 2000-706507      20001103
      US 2006-555464      20061101
      US 2006-555519      20061101
FS      PROTEIN; PS
CR      AYN11565
OS      1992-056862 [07]
MTY      protein
PSL      Example 9; SEQ ID NO 190; 181pp
DESC    Anti-oxazolone antibody N011 scFv protein. SEQ ID 190.

```

```

SCORE 195.28      93.71% of highest possible score 208.37
SCORE 1.00        100.00% of highest possible score 1.00
ALIGN
  ALIGNMENT FROM L-NUMBER L3
  Query Length: 100; Sequence Length: 249;
  Score: 195.3 bits (495), 93.7% of highest possible score 208.4;
  Expect value: 1.836e-48;
  Identities: 93 / 100 (93.0%); Positives: 97 / 100 (97.0%);
  Query Identity: 93.0%; Query Coverage: 100.0%;
  Subject Identity: 37.3%; Subject Coverage: 40.2%;
  Alignment Length: 100;
Q:   1 DVLMTQTPLSLPVSLGDQASISCRSSHYIVHSDGNTYLEWYLQKPGQSPKLLIYKVSNR 60
      |+ +|||||||||||||||||| |||+|||||||||||||||||||||||
L4                                     =====
S: 137 DIELTQTPLSLPVSLGDQASISCRSSQSIHVSNGNTYLEWYLQKPGQSPKLLIYKVSNR 196

Q:   61 SGVPDRFSGSGSGTDFTLKISRVEADLGIYYCFQGSHPV 100
      |||||||||||||||||||||+|||||||
L4  =====
S: 197 SGVPDRFSGSGSGTDFTLKISRVEADLGVYYCFQGSHPV 236

```


Enhancements in Full-text Patent Files

JPFULL, CNFULL, AUPATFULL, CANPATFULL, DEFULL, GBFULL, FRFULL

Content expansion:

- **JPFULL**: 12 million additional family records (1913-1999) added; 19.55 million family records in total
- **CNFULL**: 3 million additional design patents; > 45 million family records in total

New search options:

- New search fields **1** and display options
- The Locarno classification (/LCL) is available for design patents.
- **Numeric property search** now available, see HELP NPS for details
- **Interactive Claims Viewer** integration for JPFULL
- For JPFULL also the FI classification (/FCL) and the F-term classification (/FTERM) are available for Japanese patents and utility models back to 1960.

1

/CLM.IC	independent claims
/CLM.CG	claim group
/DET.DEN	detailed description in English
/PAS and /PAN	standardized/normalized patent assignees
/KT	Key terms
/UO and /UOS	ultimate owner /standardized

[More info in Database summary sheet or HELP CHANGE](#)

Claim Group Allows for More Relevant Claim Searching

Available in several patent fulltext files

- Available in several patent fulltext files, among them PCTFULL, EPFULL + previously mentioned files
- Search index comprised of claims belonging to the same group of an independent claim and its dependent claims
- Adds comprehensiveness and precision to your search results: Less noise compared to a search in all claims, more relevant results compared to a limited search in just a single claim
- Check the availability via CLM.CG/FA
- Claim Group search field: [/CLM.CG](https://CLM.CG)

Claim Text Searching is About Precision


Often related terms are not in the same sentence

WO 2023/175531

25. A process according to any one of claims 20 to 24, wherein d) comprises heating the suspension obtained in c) to a temperature of at least 70°C, or from 70 to 90 °C, or from 75 to 85°C, preferably for at least about 20 minutes.
26. A process according to claim 21, wherein e) involves centrifugation.
27. A process according to claim 21, wherein f) involves ultrafiltration.

(FILE 'PCTFULL' ENTERED AT 15:53:52 ON 10 OCT 2024)
DEL HIS Y

L1 941 S (CENTRIFUGAT? AND ULTRAFILTRAT?)/CLM
L2 560 S (CENTRIFUGAT? (S) ULTRAFILTRAT?)/CLM
L3 842 S (CENTRIFUGAT? (L) ULTRAFILTRAT?)/CLM.CG
L4 73 S L1 NOT CLM.CG/FA



Key Terms Enhance the Retrieval of Relevant Results

Available in all patent fulltext databases

- Key terms enhance retrieval of relevant results, and make the evaluation of results more efficient
 - represent important aspects of a patent
 - noun phrases of 1 to 5 words extracted from all English text fields (title, abstract, description, and claims) for a patent application, sorted according to their relevance; max. 30 KT per record
 - Can be analyzed to find additional concepts or new aspects
 - KT are a good summary, covering the entire text for relevant checking in full-text databases
- Key terms search field: **/KT**
- Display key terms: **D KT, D BRIEF, or D MAX**

Key Terms - Example

Key term search adds precision

```
=> FIL CNFULL
=> S (LASER(3A)SOURCE?)/KT
=> D L1 100 BRIEF
```

```
L1      ANSWER 100 OF 43546 CNFULL COPYRIGHT 2024 LNBIS on STN.
AN      46090899   CNFULL EDP 20231231  ED 20231231 UP 20231231 EDTX 20231231
        DED 20231229 DUPD 20231230 Full-text
TIEN    Measuring device and method for transparent solution
...
AB      Machine translation
        The invention discloses a measuring device and method for transparent
        solution, comprising a light source system; The light source system is
        arranged on the side of the transparent water tank, which contains the
        solution to be measured; The double-sided mirror is horizontally
        arranged on the bottom plate of the transparent water tank, and the
        single-sided mirror is arranged in the transparent water tank, and is
        obliquely arranged above the double-sided mirror; ...
KT      transparent solution; light point; transparent sink; laser light
        source; light spot sensing system; light source system; single-sided
        mirror; refracted light; refractive index; light source support; screw
        rod nut; horizontal screw rod; light transmission port; light source
        bracket; light spot induction system; horizontal screw mandrel; light
        beam; multiple light spot; mirror angle adjustment system; double-sided
        mirror; transparent water tank; multiple reflected light amplification;
        screw mandrel driving motor; light reflection system; light intensity;
        concentration display screen; laser beam; lead screw nut; newton ring;
        abbe refractometer
```

Key Terms - Example

Basic index search also contains noise (1/2)

=> FIL CNFULL

=> S (LASER(3A)SOURCE?)/BI

=> D L2 100 BRIEF

L3 ANSWER 100 OF 124938 CNFULL COPYRIGHT 2024 LNBIS on STN.

AN 46165549 CNFULL EDP 20240107 ED 20240107 UP 20240107 EDTX 20240107

DED 20240105 DUPD 20240106 Full-text

TIEN Experimental device and method of pulsed submerged buoyancy jet based on particle image velocity

...

AB Machine translation

The present invention relates to the technical field of buoyancy jet measurement, discloses a pulsed type submerged buoyancy jet experimental device based on particle image velocity, this buoyant jet experimental device comprises, it comprises a water circulation assembly, a drainage pipeline connected with the water outlet of a constant water tank in the water circulation assembly, and a jet pipe fitting connected to the output end of the drainage pipeline, and the jet pipe fitting is arranged in the water tank; The synchronizer that is electrically connected with the computer and the laser and the camera that are electrically connected with the synchronizer, and the piece light source that is arranged at the output end of the **laser**; the piece light **source** is arranged above the outlet of the jet pipe fitting, and the shooting direction of the camera is perpendicular to the middle section of the outlet of the jet pipe fitting; the present invention component is an experimental device for exploring the pulsed submerged buoyancy jet, ...

Key Terms - Example

Basic index search also contains noise (2/2)

...

KT submerged buoyancy jet; particle image velocity; experimental device; jet pipe fitting; constant water tank; jet tube; water pipe; water circulation assembly; frame side wall; constant water level; experimental water jet; preset experimental parameter; drainage pipe; box side wall; inlet pipe; water heater; output end; water outlet; triangular extrusion block; buoyancy jet experiment; experimental water body; jet flow; toothed plate; hot water jet; pulsed intermittent jet phenomena; buoyant jet; jet body; pulsed intermittent buoyancy jet; deflection rod; connecting plate

Japanese Patent Classifications – FI and F-Terms

Available in DWPI, INPADOC, JPFULL for 16 mio inventions

– FI Patent Classification:

- Applied to all Japanese patents and utility models
- Comprises more than 190.000 codes compared to 70.000 of the IPC

=> S **A01G0031-00** **601** **C**/FCL facet

file discrimination
symbol

IPC symbol IPC
subdivision

- Thesarus functionality attached to **/FCL** field in DWPI, INPADOC and JPFULL
 - FI thesaurus is new to INPADOC and JPFULL and replaces the old version in DWPI
 - EXPAND - view the definition of the codes and related hierarchies
 - SEARCH - include broader and narrower terms of the hierarchy

=> **HELP JPC**

FI Thesaurus Applications - Examples

[View definition of FI code](#) / [Search FI code with all narrower codes](#) / [View scope notes](#)

=> E A61K0031-74+TI/FCL

E1	0	BT4	A/FCL
E2	0	BT3	A61/FCL
		DEF	MEDICAL OR VETERINARY SCIENCE; HYGIENE
E3	372133	BT2	A61K/FCL
		DEF	PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J 3/00; chemical
E4	4868	BT1	A61K0031-00/FCL
		DEF	Medicinal preparations containing organic active ingredients (2)
E5	155	-->	A61K0031-74/FCL
		DEF	. Synthetic polymeric materials (2)

***** END *****

=> E A61K0031-74+NT/FCL

E1	155	-->	A61K0031-74/FCL
		DEF	. Synthetic polymeric materials (2)
E2	49	NT1	A61K0031-745/FCL
		DEF	. . Polymers of hydrocarbons (2)
E3	14	NT2	A61K0031-75/FCL
		DEF	. . . of ethene (2)
E4	20	NT1	A61K0031-755/FCL
		DEF	. . Polymers containing halogen (2)

=> S A61K0031-74+NT/FCL

L1 2333 A61K0031-74+NT/FCL (14 TERMS)

=> E A61K+NOTE/FCL

E1	372133	-->	A61K/FCL
		NOTE	This subclass covers the following subject matter, whether set forth as a composition (mixture), process of preparing the composition or process of treating using the composition:(1,7,8) Drug or other biological compositions which are capable of:

CABA Enhancements

CABA contains > 12M records on agriculture, biotechnology, crop science, engineering, environment, food technology, genetics, human and veterinary medicine

- 1973 – present, weekly updates
- **Numeric property search** now available, see HELP NPS for details
- All author affiliations are now supplied:

```
AU  Patel, Femida Yunus (1); Shah, Neil Jaykumar (1); Upreti,  
    Kaushal Kishore (2); Laxman, Ramanna Hunashikatti (2)  
CS  (1)Agri Biochem Research Lab, M/s. Pushpa J. Shah, GIDC  
    Panoli, Ankleshwar 394116, India  
    (2)Division of Biosciences, Indian Institute of  
    Horticulture Research, Indian Council of Agriculture  
    Research, Bengaluru 560089, India  
    EMAIL: neil@pushpajshah.com
```

RAPRA, CEABA, TEMA enhancements

- Produced by WTI AG
- Backfile data 2022-present now available, with weekly updates
- **RAPRA (Polymer Library):**
rubber, plastics, adhesives and polymer composites (1972 -)
- **CEABA (Chemical Engineering and Biotechnology Abstracts)** (1966 -)
- **TEMA (Technology and Management):**
multidisciplinary technology database incl. business information, useful for medical engineering, textile and paper, energy, mechanical and plant engineering, information technology (1968 -)

Pharmaceutical Substances (PS) Database Expands

- Active Pharmaceutical Ingredients (API) collection has been expanded
- New categories include kinase inhibitors, anti-obesity medications, and drugs for rare diseases
- PS, produced by Thieme, now includes essential information for about 2900 active pharmaceutical ingredients, including preparation methods and trade data.

Agenda

- STN Interface enhancements
- Database enhancements and reloads
 - Enhancements to full-text patent files
- Ultimate Owner/acquisition of patent rights
- Unitary Patent Information

Identification of the Current Owner of a Patent

Ultimate Owner fields added to additional databases

- Company name changes, mergers, acquisitions can often complicate an organization-based IP search
- **Ultimate owner shows the latest owner of IP rights**
- Available in 10+ files, including Caplus, MARPAT, INPADOCDB, and USPATFULL and other full text files
 - /UO** Ultimate owner
 - /UOS** Ultimate owner standardized
- Data obtained from PatentSight through their manual and algorithmic curation of IP ownership and M&A analysis
 - Significant effort to reduce spelling errors and further standardization
 - Does not provide historical changes or date of transfer of IP rights
 - Updated weekly
- Available to all STN users

Acquisition of Patent Rights

Which patents not originally assigned to Amgen did they purchase?

L1 1334 S AMGEN/UO NOT AMGEN/PA

L1 ANSWER 1 OF 1334 CAPLUS COPYRIGHT 2024 ACS on STN
TI Engineering of CD19 antibodies for treatment and prevention of
immune-mediated necrotizing myopathy
IN Rampal, Nishi; Wu, Yanping
PA Viela Bio, Inc., USA
UO **AMGEN** INC
UOS Amgen
PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2024155810	A1	20240725	WO 2024-US12011	20240118

L1 ANSWER 4 OF 1334 CAPLUS COPYRIGHT 2024 ACS on STN
TI Methods for treating inactive or chronic thyroid eye disease
IN Thompson, Elizabeth H. Z.; Sherman, Jeffrey Wayne
PA Horizon Therapeutics Ireland Dac, Ire.
UO **AMGEN** INC
UOS Amgen
PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2024069236	A1	20240404	WO 2023-IB595	20230928
US 20240109970	A1	20240404	US 2023-18477140	20230928
UY 40458	A	20240415	UY 2023-40458	20230928

Acquisition of Patent Rights

Which patents not originally assigned to Amgen did they purchase?

```
L1 1334 S AMGEN/UO NOT AMGEN/PA
L2      ANALYZE L1 1- PA :      260 TERMS
```

TERM #	# OCC	# DOC	% DOC PA				
1	128	128	9.60	CHEMOCENTRYX INC USA	9	36	36 2.70 NUEVOLUTION A S DEN
2	107	107	8.02	DECODE GENETICS EHF ICELAND	10	32	32 2.40 SYNERGEN INC USA
3	107	107	8.02	IMMUNEX CORP USA	11	30	30 2.25 ONYX PHARMACEUTICALS INC USA
4	94	94	7.05	FIVE PRIME THERAPEUTICS INC USA	12	26	26 1.95 BIO TECHNOLOGY GENERAL CORP USA
5	92	92	6.90	IMMUNEX CORPORATION USA	13	24	24 1.80 MICROMET AG GERMANY
6	74	74	5.55	USA	14	22	22 1.65 ONYX THERAPEUTICS INC USA
7	69	69	5.17	TULARIK INC USA	15	22	22 1.65 TENEObIO INC USA
8	39	39	2.92	CELGENE CORPORATION USA	16	15	15 1.12 HORIZON THERAPEUTICS IRELAND DAC IRE

Unitary Patents in CAS STNext

In effect since June 2023

Existing patent families with EP patents are updated with new EP C0 family members

- UP participating states with specific display and search options

INPADOC legal events for UP include:

- events for the unitary patent protection (legal status category UER)
- Unified Patent Court opt-out events (legal status category UOO)
- usual post grant events as fee payment, licensing, lapse, or withdrawal are available

Status indicator for EP C0 in INPADOC and CAplus

Unitary patent and UPC opt-out monitoring

=> HELP UNITARYPATENT

CAplus

DWPI

INPADOC

EPFULL

Unified Patent Court Opt-Outs

Which EP patents of BASF were opted-out of the UPC jurisdiction?

Unified patent court (UPC) is the new international court to decide on the infringement and validity of **classic EP patents** and **unitary patents**

- For a transitional period of 7 years, opt-out of the UPC jurisdiction is possible for classic EP patents.

1

=> FIL INPADOCDB


=> S BASF/PASS AND U00/LSC2 (L) UPLS/LAST

```
L20 ANSWER 1 OF 1332 INPADOCDB COPYRIGHT 2024 EPO/FIZ KA on STN
PI EP 4263766 A2 20231025
PA BASF SE
PAS BASF SE, DE

AN 123957226 INPADOCDB Full-text

LEGAL STATUS
20240619 EPP01 OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT
(UPC) REGISTERED
20240513
U00 Opt-out of UPC Jurisdiction
W OTHER
.....20240627
```

2



STNext alert feature
requires query L1 and
the **update code UPLS**
as a **linked alert via (L)**

Unified Patent Court Opt-Outs

Which EP patents of BASF were opted-out of the UPC jurisdiction?


Unified patent court (UPC) is the new international court to decide on the infringement and validity of **classic EP patents** and **unitary patents**

- For a transitional period of 7 years, opt-out of the UPC jurisdiction is possible for classic EP patents.

1

```
=> FIL INPADOCDB  
  
=> S BASF/PASS AND U00/LSC2
```

2



STNext alert feature
requires query L1
and the **update
code UPLS**

LSC Opt-out codes*	Description
EPP01	OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) REGISTERED
EPP02	OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) CHANGED
EPP03	OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) DELETED
EPP04	WITHDRAWAL OF OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) REGISTERED
EPP05	WITHDRAWAL OF OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) CHANGED
EPP06	WITHDRAWAL OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) DELETED

Differences in Claim Text

Application and grant changes for EP1908753

— Claims 3 of the application:

3. A transient receptor potential type I (TRPV1) receptor antagonist comprising, as an active ingredient, at least one of the compound represented by formula (I') according to Claim 1, a pharmaceutically acceptable salt of the compound, and a solvate of the compound or the salt.

— Claim 4 of the grant:

4. The pharmaceutical composition according to claim 3, wherein the at least one other drug is selected from the group consisting of an opioid agonist, gabapentin, pregabalin, an antidepressant drug, an antiepileptic drug, an antiarrhythmic drug, a NSAID, an antiinflammatory drug and a COX-2 inhibitor.

— Gabapentin was mentioned in the description of the original application:

[0404] The compound of the present invention can be used in combination with other drugs.

[0405] Examples of the drugs include analgetic drugs such as opioid agonists, e.g., morphine; gabapentin; Pregabalin; antidepressant drugs such as Duloxetine and amitriptyline; antiepileptic drugs such as carbamazepine and phenytoin; antiarrhythmic drugs, such as mexiletine, which are alternatively used and prescribed for neuropathic pain; NSAIDs such as diclofenac, indomethacin, ibuprofen, and naproxen; and anti-inflammatory drugs such as COX-2 inhibitors, e.g.,

Claims Comparison in Interactive Claim Viewer **Beta**

Available for EPFULL, PCTFULL and JPFULL

- A **graphical claims** tree depicting the relationships between independent and dependent claims
- For different documents in a national patent family, claims comparison is available
- Claim texts are available for each claim on the right panel

3

View Single Graph ☒ Text

EP4160090A1

Claims for EP4160090A1 - LAMP

1.[CLM0001] A lamp, characterized by comprising:
a body (1);
a mounting plate (2) mounted with an electrical assembly (3) and having a clamping member (21) and an end, wherein the end is provided with a first positioning groove (22);
a clamping plate (4) fixed on the body (1); and
a positioning member (5) comprising a positioning plate (6) fixed on the body (1) and a knob (7) movable along a vertical direction and rotatable around an axis of the knob (7), wherein the knob (7) is provided with a first protrusion (71), and the first protrusion (71) is configured to engage with the first positioning groove (22) and drive the clamping member (21) to abut against the clamping plate (4).

2.[CLM0002] The lamp as claimed in claim 1, wherein a plurality of clamping members (21) are arranged on the mounting plate (2) at intervals, clamping plates (4) and the clamping members (21) are consistent in number, and the clamping plates (4) are in one-to-one alignment with the clamping members (21).

3.[CLM0003] The lamp as claimed in claim 1, wherein the clamping member (21) comprises an extension portion (23) bent toward a side of the mounting plate (2) close to the body (1), and a gap is formed between the extension portion (23) and the mounting plate (2) to receive the clamping plate (4).

4.[CLM0004] The lamp as claimed in claim 1, wherein the positioning member (5) further comprises a guiding rod (8), the guiding rod (8) comprises a head (81) and a rod (82) connected to the head (81), the knob (7) is provided with a through hole (73) for the rod (82) to pass through and abut against the head (81), an outer wall of the rod (82) is provided with a thread, and the body (1) is provided with a first threaded hole (12) to engage with the rod (82).

6.[CLM0006] The lamp as claimed in claim 1, wherein the knob (7) is provided with a plurality of first protrusions (71), the plurality of first protrusions (71) are arranged at intervals along a length direction of one side of the mounting plate (2) close to the knob (7), a plurality of first positioning grooves (22) are consistent with the plurality of first protrusions (71) in number, and a distance between every two adjacent first positioning grooves (22) is consistent with a distance between every two adjacent first protrusions (71).

EP4160090B1

Claims for EP4160090B1 - LAMP

1.[CLM0001] A lamp, comprising
a body (1);
a mounting plate (2) mounted with an electrical assembly (3) and having a clamping member (21) and an end, wherein the end is provided with a first positioning groove (22);
a clamping plate (4) fixed on the body (1); and
a positioning member (5) comprising a positioning plate (6) fixed on the body (1) and a knob (7) movable along a vertical direction and rotatable around an axis of the knob (7), wherein the knob (7) is provided with a first protrusion (71), and the first protrusion (71) is configured to engage with the first positioning groove (22) and drive the clamping member (21) to abut against the clamping plate (4).

2.[CLM0002] The lamp as claimed in claim 1, wherein a plurality of clamping members (21) are arranged on the mounting plate (2) at intervals, clamping plates (4) and the clamping members (21) are consistent in number, and the clamping plates (4) are in one-to-one alignment with the clamping members (21).

3.[CLM0003] The lamp as claimed in claim 1, wherein the clamping member (21) comprises an extension portion (23) bent toward a side of the mounting plate (2) close to the body (1), and a gap is formed between the extension portion (23) and the mounting plate (2) to receive the clamping plate (4).

4.[CLM0004] The lamp as claimed in claim 1, wherein the positioning member (5) further comprises a guiding rod (8), the guiding rod (8) comprises a head (81) and a rod (82) connected to the head (81), the knob (7) is provided with a through hole (73) for the rod (82) to pass through and abut against the head (81), an outer wall of the rod (82) is provided with a thread, and the body (1) is provided with a first threaded hole (12) to engage with the rod (82).

6.[CLM0006] The lamp as claimed in claim 1, wherein the knob (7) is provided with a plurality of first protrusions (71), the plurality of first protrusions (71) are arranged at intervals along a length direction of one side of the mounting plate (2) close to the knob (7), a plurality of first positioning grooves (22) are consistent with the plurality of first protrusions (71) in number, and a distance between every two adjacent first positioning grooves (22) is consistent with a distance between every two adjacent first protrusions (71).

1

PI EP 4160090

DS R: AL AT BE LV MC MK

U: AT BE BG

PIT EPC0 UNITARY

AI EP 2022-17823

PRAI CN 2021-22384

IPCI F21V0023-02

Full-text options

Legal status

Claims Viewer BETA

Register Links

English language equivalents


Extended patent family information

2


Compare With ▲

EP4160090B1

EP4160090C0



Latest CAS STNext Application & Content Updates



CAS STNext

The world's premier solution for scientific, technical and IP research

- Unique content
- Unparalleled power and precision
- Proven reliability


[Learn more](#)

Username

Password

☐ Keep me signed in

Log In




Help My Files Larissa Bergmann

History Project CAS Settings es

Session

What's New

Logoff



CAS STNext

What's New in STNext?

View the latest STNext application and content updates.

Welcome to STNext What's New in STNext? Searching CAS Sequences Working with Search Results Managing Your Files and Projects

CAS STNext / What's New in STNext?

Welcome to STNext

What's New in STNext?

Latest STN News

September 9: Recent Reloads of CANPATFULL, DEFULL and GBFULL Feature Addition of Ultimate Owner Information

August 3, 2024: PatentPak Links Now Available in MARPAT

July 7, 2024: New Search Enhancements

Effective August 3, 2024, PatentPak links will be presented in MARPAT records, as available. About half of all MARPAT records will include...

The patent full text databases CANPATFULL (reporting Canadian patents), DEFULL (German patents) and GBFULL (United Kingdom patents) have been reloaded.

June 25, 2024: CABA Reload Features Comprehensive Author Affiliations and Additional Numeric Properties

May 17, 2024: EMTREE Update Provides Latest Biomedical Terminology for Searching

The CABA file has been reloaded. Key changes are: All author affiliations are now supplied, and to support this, the displays of the A...

The newest version of the Emtree thesaurus launched in Embase on STNext on May 13, 2024. Emtree is a critical resource for the most up-to-date...

Thank you

Sarah W. Stokes

Senior Product Specialist, IP
ssstokes@cas.org

CONTACT

CAS

help@cas.org
cas.org

EMEA Help

EMEAhelp@cas.org

